Cargando…

Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia

Although a 2 g once daily administration of ceftriaxone remains the standard dosing regimen for the treatment of aspiration pneumonia, there are no studies to investigate the optimal dosing method. Hence, we retrospectively evaluated the effectiveness and safety of 1 g twice daily versus 2 g once da...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Hideo, Hagihara, Mao, Morikawa, Yoshihiko, Asai, Nobuhiro, Mikamo, Hiroshige, Iwamoto, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331887/
https://www.ncbi.nlm.nih.gov/pubmed/35892373
http://dx.doi.org/10.3390/antibiotics11080983
_version_ 1784758512392339456
author Kato, Hideo
Hagihara, Mao
Morikawa, Yoshihiko
Asai, Nobuhiro
Mikamo, Hiroshige
Iwamoto, Takuya
author_facet Kato, Hideo
Hagihara, Mao
Morikawa, Yoshihiko
Asai, Nobuhiro
Mikamo, Hiroshige
Iwamoto, Takuya
author_sort Kato, Hideo
collection PubMed
description Although a 2 g once daily administration of ceftriaxone remains the standard dosing regimen for the treatment of aspiration pneumonia, there are no studies to investigate the optimal dosing method. Hence, we retrospectively evaluated the effectiveness and safety of 1 g twice daily versus 2 g once daily administration of ceftriaxone in adult patients with aspiration pneumonia. Patients who received ceftriaxone for the treatment of aspiration pneumonia between 2015 and 2021 were included in this study. Clinical responses, inflammatory markers, and incidence of adverse events after completion of ceftriaxone therapy were investigated. In total, 33 patients received 1 g twice daily (group 1) and 28 received 2 g once daily (group 2) ceftriaxone for the treatment of mild-to-moderate aspiration pneumonia. Compared with that of group 1, group 2 demonstrated significantly improved clinical responses (group 1 vs. group 2, 84.8% vs. 100%, p = 0.0316). Although the safety profile was not significantly different between the two groups, the incidence of choleliths during ceftriaxone therapy in group 1 was higher than that in group 2 (31.3% vs. 9.1%, p = 0.174). Therefore, a 2 g once daily administration of ceftriaxone appeared to be a simple regimen adequate for the treatment of inpatients with mild-to-moderate aspiration pneumonia, which might not be heavily involved by anaerobes.
format Online
Article
Text
id pubmed-9331887
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93318872022-07-29 Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia Kato, Hideo Hagihara, Mao Morikawa, Yoshihiko Asai, Nobuhiro Mikamo, Hiroshige Iwamoto, Takuya Antibiotics (Basel) Article Although a 2 g once daily administration of ceftriaxone remains the standard dosing regimen for the treatment of aspiration pneumonia, there are no studies to investigate the optimal dosing method. Hence, we retrospectively evaluated the effectiveness and safety of 1 g twice daily versus 2 g once daily administration of ceftriaxone in adult patients with aspiration pneumonia. Patients who received ceftriaxone for the treatment of aspiration pneumonia between 2015 and 2021 were included in this study. Clinical responses, inflammatory markers, and incidence of adverse events after completion of ceftriaxone therapy were investigated. In total, 33 patients received 1 g twice daily (group 1) and 28 received 2 g once daily (group 2) ceftriaxone for the treatment of mild-to-moderate aspiration pneumonia. Compared with that of group 1, group 2 demonstrated significantly improved clinical responses (group 1 vs. group 2, 84.8% vs. 100%, p = 0.0316). Although the safety profile was not significantly different between the two groups, the incidence of choleliths during ceftriaxone therapy in group 1 was higher than that in group 2 (31.3% vs. 9.1%, p = 0.174). Therefore, a 2 g once daily administration of ceftriaxone appeared to be a simple regimen adequate for the treatment of inpatients with mild-to-moderate aspiration pneumonia, which might not be heavily involved by anaerobes. MDPI 2022-07-22 /pmc/articles/PMC9331887/ /pubmed/35892373 http://dx.doi.org/10.3390/antibiotics11080983 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kato, Hideo
Hagihara, Mao
Morikawa, Yoshihiko
Asai, Nobuhiro
Mikamo, Hiroshige
Iwamoto, Takuya
Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia
title Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia
title_full Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia
title_fullStr Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia
title_full_unstemmed Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia
title_short Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia
title_sort retrospective comparison of the effectiveness and safety of ceftriaxone 1 g twice daily versus 2 g once daily for treatment of aspiration pneumonia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331887/
https://www.ncbi.nlm.nih.gov/pubmed/35892373
http://dx.doi.org/10.3390/antibiotics11080983
work_keys_str_mv AT katohideo retrospectivecomparisonoftheeffectivenessandsafetyofceftriaxone1gtwicedailyversus2goncedailyfortreatmentofaspirationpneumonia
AT hagiharamao retrospectivecomparisonoftheeffectivenessandsafetyofceftriaxone1gtwicedailyversus2goncedailyfortreatmentofaspirationpneumonia
AT morikawayoshihiko retrospectivecomparisonoftheeffectivenessandsafetyofceftriaxone1gtwicedailyversus2goncedailyfortreatmentofaspirationpneumonia
AT asainobuhiro retrospectivecomparisonoftheeffectivenessandsafetyofceftriaxone1gtwicedailyversus2goncedailyfortreatmentofaspirationpneumonia
AT mikamohiroshige retrospectivecomparisonoftheeffectivenessandsafetyofceftriaxone1gtwicedailyversus2goncedailyfortreatmentofaspirationpneumonia
AT iwamototakuya retrospectivecomparisonoftheeffectivenessandsafetyofceftriaxone1gtwicedailyversus2goncedailyfortreatmentofaspirationpneumonia